(Q38608986)

4 September 2017

title

Prospects for adoptive immunotherapy of pancreatic cancer using chimeric antigen receptor-engineered T-cells (English)

1 reference

4 September 2017

1 reference

1 reference

John Maher

3

0 references

author name string

Doraid Alrifai

series ordinal

1

1 reference

4 September 2017

Debashis Sarker

series ordinal

2

1 reference

4 September 2017

publication date

16 October 2015

1 reference

Immunopharmacology and Immunotoxicology

4 September 2017

published in

1 reference

4 September 2017

volume

38

1 reference

4 September 2017

issue

1

1 reference

4 September 2017

page(s)

50-60

1 reference

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Gene and cell therapy for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Tumor antigen-specific monoclonal antibodies and induction of T-cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Exploiting the curative potential of adoptive T-cell therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Clinical immunotherapy of B-cell malignancy using CD19-targeted CAR T-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

What is recent in pancreatic cancer immunotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

T cells and adoptive immunotherapy: recent developments and future prospects in gastrointestinal oncology.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Targeting IL-17B-IL-17RB signaling with an anti-IL-17RB antibody blocks pancreatic cancer metastasis by silencing multiple chemokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Inflammatory networks and immune surveillance of pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Complex role for the immune system in initiation and progression of pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Current advances in immunotherapy for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Whole blood interferon-γ levels predict the therapeutic effects of adoptive T-cell therapy in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Ex vivo expanded telomerase-specific T cells are effective in an orthotopic mouse model for pancreatic adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Generation of tumor-infiltrating lymphocytes from pancreatic cancer lesions for cellular therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Cancer/testis (CT) antigens: potential targets for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Expression of cancer testis antigens in pancreatic carcinoma cell lines, pancreatic adenocarcinoma and chronic pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

The role of classical and non-classical HLA class I antigens in human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Immunotherapy with gene-modified T cells: limiting side effects provides new challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Sleeping beauty system to redirect T-cell specificity for human applications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Large volume flow electroporation of mRNA: clinical scale process

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Immune responses to transgene and retroviral vector in patients treated with ex vivo–engineered T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Chimeric antigen receptor T cells for sustained remissions in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Managing cytokine release syndrome associated with novel T cell-engaging therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Identification of pancreatic cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)Bi-C595 radioimmunoconjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Aberrant expression of mucin core proteins and o-linked glycans associated with progression of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

The metal ion-induced cooperative binding of HIV-1 integrase to DNA exhibits a marked preference for Mn(II) rather than Mg(II).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

CAR mechanics: driving T cells into the MUC of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Kinetics of tumor destruction by chimeric antigen receptor-modified T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Engineered T cells for pancreatic cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Membrane-associated heparan sulfate proteoglycans are involved in the recognition of cellular targets by NKp30 and NKp46.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Discovery of mesothelin and exploiting it as a target for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: identifying a window of therapeutic opportunity?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Inducible apoptosis as a safety switch for adoptive cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Manufacturing models permitting roll out/scale out of clinically led autologous cell therapies: regulatory and scientific challenges for comparability.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2015.1100204

10.3109/08923973.2015.1100204

21 January 2018

Identifiers

DOI

1 reference

4 September 2017

1 reference